Trial · NCT07559045
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response (CR) Rate at 3 Months After Radiotherapy (Investigator-Assessed) | 3 months after completion of radiotherapy | Proportion of patients achieving complete response (CR) per RECIST 1.1, assessed by investigators at 3 months after completion of radiotherapy |
| Primary | 1-Year Progression-Free Survival (PFS) Rate | 1 year after randomization | Proportion of patients alive and without disease progression at 1 year after randomization |
| Secondary | Overall Survival (OS) | Up to 3 years after randomization | Time from randomization to death from any cause |
| Secondary | Progression-Free Survival (PFS) | Up to 3 years after randomization | Time from randomization to first documented disease progression or death from any cause, whichever occurs first |
| Secondary | Duration of Response (DOR) | Up to 3 years after randomization | Time from first documentation of objective response (CR/PR) to first documented disease progression or death |
| Secondary | Objective Response Rate (ORR) | Up to 3 years after randomization | Proportion of patients achieving CR or partial response (PR) per RECIST 1.1 |
| Secondary | Local Regional Failure-Free Survival (LRFS) | Up to 3 years after randomization | Time from randomization to first local or regional recurrence or death |
| Secondary | Distant Metastasis-Free Survival (DMFS) | Up to 3 years after randomization | Time from randomization to first distant metastasis or death |
| Secondary | Incidence of Treatment-Emergent Adverse Events (TEAEs) | From first study treatment to 30 days after last treatment | Incidence and severity of TEAEs (graded per CTCAE 5.0) during treatment and follow-up |
| Secondary | EORTC QLQ-OES18 Symptom Score Change | Baseline, 3 months, 6 months, 12 months after radiotherapy | Change in esophageal cancer-specific symptom score as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Oesophageal 18 (EORTC QLQ-OES18) from baseline to post-treatment follow-ups. The scale ranges from 0 to 100, with higher scores indicating more severe symptoms and worse quality of life. |
| Secondary | EORTC QLQ-C30 Quality of Life Score Change | Baseline, 3 months, 6 months, 12 months after radiotherapy. | Change in quality of life score as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) from baseline to post-treatment follow-ups. The scale ranges from 0 to 100, with higher scores indicating better quality of life. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07559045/registered